BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project

BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project

Windsor, Nova Scotia, Canada (March 7, 2019) – On March 6, 2019, BIOVECTRA Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), hosted a roundtable discussion at its Windsor, Nova Scotia facility to discuss the local impact of the planned five-year, $144.6 million expansion project announced on March 4 in Charlottetown, PEI. Community roundtable voices included Bernadette Jordan, Minister of Rural Economic Development, the Atlantic Canadian Opportunity Agency (ACOA), Innovation, Science and Economic Development (ISED), municipal leaders including Mayors Anna Allen and Peter Muttart, key industry association leaders, Acadia University and Nova Scotia Community College (NSCC) representatives, and local business representatives.

In support of the expected $144.6 million expansion project, BIOVECTRA received a $37.5 million investment through the Government of Canada’s Strategic Innovation Fund. Over the five-year lifespan of the project, the company intends to create 150 jobs in Atlantic Canada, with 110 anticipated in Windsor, Nova Scotia.

“We’re proud to be a partner with BIOVECTRA in creating well-paying jobs here in the Maritimes. This funding will allow BIOVECTRA to expand its manufacturing capacity and start research and development of advanced pharmaceutical products not currently manufactured in Canada, helping to position the Maritimes as an innovative hub for these products that save lives.” – The Honourable Bernadette Jordan, Minister of Rural Economic Development

The roundtable discussion focused on understanding and supporting the project itself, but also on leveraging the collective contributions and strengths of all stakeholders in creating a climate to capture and create more opportunities like this one for long-term regional growth. “This invaluable exchange was focused on community collaboration,” said BIOVECTRA’s Windsor General Manager, Heather Delage. “This discussion was all about building momentum and bringing the right people to the table that can help create an environment and action plan to support our investment.”


BIOVECTRA is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BIOVECTRA has over 45 years of experience specializing in:

For more information about BIOVECTRA, please visit

Media Contact

Jordan MacGregor
Communications and Marketing Manager
Phone: 902-566-9116 ext. 6376
E-Mail: [email protected]

Statements in this document that are not strictly historical, including statements regarding future business prospects, use of capital or the impact of any such events or developments, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. The forward-looking statements made herein speak only as of the date hereof and the company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors